LingHui David Su, Charles Y Chiu, David Gaston, Catherine A Hogan, Steve Miller, Dennis W Simon, Kiran T Thakur, Shangxin Yang, Anne Piantadosi
Central nervous system (CNS) infections carry a substantial burden of morbidity and mortality worldwide, and accurate and timely diagnosis is required to optimize management. Metagenomic next-generation sequencing (mNGS) has proven to be a valuable tool in detecting pathogens in patients with suspected CNS infection. By sequencing microbial nucleic acids present in a patient's cerebrospinal fluid, brain tissue, or samples collected outside of the CNS, such as plasma, mNGS can detect a wide range of pathogens, including rare, unexpected, and/or fastidious organisms...
July 11, 2024: Molecular Diagnosis & Therapy
Sushmita Singha, Neena Nath, Vaishali Sarma, Kangkana Barman, Gurumayum Chourajit Sharma, Lahari Saikia, Shashi Baruah
BACKGROUND AND OBJECTIVE: Dengue is a major infectious disease with potential for outbreaks and epidemics. A specific and sensitive diagnosis is a prerequisite for clinical management of the disease. We designed our study to identify epitopes on the Dengue virus (DENV) envelope (E) and non-structural protein 1 (NS1) with potential for diagnosis. METHODS: Serology and immunoinformatic approaches were employed. We collected DENV-positive, DENV-negative and Japanese encephalitis virus-positive samples from collaborating hospitals in 2019 and 2022-2023...
July 9, 2024: Molecular Diagnosis & Therapy
Yi Liu, Xiaojun Chen, Huaiwu Lu, Xin Wu, Xuehan Liu, Fei Xu, Dongdong Ye, Bo Ding, Xiaoyan Lu, Ling Qiu, Jing Zhu, Yingying Wang, Xinya Huang, Zhen Shen, Tao Zhu, Yang Shen, Ying Zhou
BACKGROUND: There is no consensus regarding the specific genes included in the homologous recombination repair (HRR) gene panel for identifying the HRR deficiency (HRD) status and predicting the prognosis of epithelial ovarian cancer (EOC) patients. OBJECTIVE: We aimed to explore a 15-gene panel involving the HRR pathway as a predictive prognostic indicator in Chinese patients newly diagnosed with EOC. PATIENTS AND METHODS: We reviewed the previously published reports about different HRR gene panels and prespecified the 15-gene panel...
July 5, 2024: Molecular Diagnosis & Therapy
Rizwan Qaisar, Asima Karim, M Shahid Iqbal, Firdos Ahmad, M Azhar Hussain
OBJECTIVES: Plasma C-terminal agrin-fragment-22 (CAF22), a breakdown product of neuromuscular junction, is a potential biomarker of muscle loss. However, its levels from adolescence to octogenarians are unknown. METHODS: We evaluated young (18-34 years, n = 203), middle-aged (35-59 years, n = 163), and old men (60-87 years, n = 143) for CAF22, handgrip strength (HGS), appendicular skeletal-mass index (ASMI), and gait speed. RESULTS: We found an age-associated increase in CAF22 from young (100...
July 3, 2024: Molecular Diagnosis & Therapy
Michelle E McClements, Maram E A Abdalla Elsayed, Lauren Major, Cristina Martinez-Fernandez de la Camara, Robert E MacLaren
Gene therapies have emerged as promising treatments in clinical development for various retinal disorders, offering hope to patients with inherited degenerative eye conditions. Several gene therapies have already shown remarkable success in clinical trials, with significant improvements observed in visual acuity and the preservation of retinal function. A multitude of gene therapies have now been delivered safely in human clinical trials for a wide range of inherited retinal disorders but there are some gaps in the reported trial data...
July 2, 2024: Molecular Diagnosis & Therapy
Qiang Wang, Bo Yu, Shuilong Zhang, Dongliang Wang, Zhifu Xiao, Hongjing Meng, Lingxiang Dong, Yuhang Zhang, Jie Wu, Zebin Hou, Yunji Zhu, Dewei Li
BACKGROUND: Thyroid cancer is prevalent worldwide, including in China, where its incidence is on the rise. Papillary thyroid carcinoma (PTC) is the predominant subtype. Investigating the relationship between clinical data associated with PTC and gene mutations is crucial for improving detection and treatment. PATIENTS AND METHODS: We collected samples and associated clinical data from 700 PTC patients at Shanxi Provincial People's Hospital. Using a panel of 57 genes linked to thyroid cancer, we sequenced the samples to determine the mutation frequency of thyroid cancer-associated genes in PTC...
June 19, 2024: Molecular Diagnosis & Therapy
Sercan Ergün, Senanur Aslan, Dilbeste Demir, Sümeyye Kayaoğlu, Mevsim Saydam, Yeda Keleş, Damla Kolcuoğlu, Neslihan Taşkurt Hekim, Sezgin Güneş
Apoptosis, or programmed cell death, maintains tissue homeostasis by eliminating damaged or unnecessary cells. However, cells can evade this process, contributing to conditions such as cancer. Escape mechanisms include anoikis, mitochondrial DNA depletion, cellular FLICE inhibitory protein (c-FLIP), endosomal sorting complexes required for transport (ESCRT), mitotic slippage, anastasis, and blebbishield formation. Anoikis, triggered by cell detachment from the extracellular matrix, is pivotal in cancer research due to its role in cellular survival and metastasis...
June 18, 2024: Molecular Diagnosis & Therapy
Sohita Dhillon
Zevorcabtagene autoleucel () is a fully humanised B cell maturation antigen (BCMA)-targeting specific chimeric antigen receptor (CAR) T-cell therapy being developed by CARsgen for the treatment of multiple myeloma. Zevorcabtagene autoleucel is an autologous CAR T cell comprising a fully human BCMA-specific scFv (25C2), a CD8α hinge region and transmembrane domain, a 4-1BB costimulatory domain and a CD3-ζ T cell activation domain. Zevorcabtagene autoleucel recognizes and induces selective toxicity against BCMA-expressing tumour cells leading to their elimination...
June 18, 2024: Molecular Diagnosis & Therapy
Xiaodong Song, Linlin Duan, Yongshuai Dong
PURPOSE: Globally, non-small cell lung cancer (NSCLC) is the primary cause of cancer-related mortality, both early and accurate diagnosis are essential for effective treatment and improved patient outcomes. Exosomal noncoding RNAs (ncRNAs) have emerged as promising biomarkers for NSCLC diagnosis. This meta-analysis aims to assess the diagnostic accuracy of exosomal long noncoding RNAs (lncRNAs) for diagnosing NSCLC. METHODS: A comprehensive literature search was conducted to identify relevant studies that assessed the diagnostic performance of exosomal lncRNAs in NSCLC...
June 5, 2024: Molecular Diagnosis & Therapy
Erika A Bastos-Soares, Michelle Suelen da Silva Morais, Maribel Funes-Huacca, Rosa Maria O Sousa, Nairo Brilhante-Da-Silva, Sibele Andrade Roberto, Nidiane Dantas R Prado, Claudia N Duarte Dos Santos, Anna C M Marinho, Andreimar M Soares, Rodrigo G Stabeli, Soraya Dos Santos Pereira, Carla Freire C Fernandes
INTRODUCTION: Hantavirus, a zoonotic pathogen, causes severe syndromes like hemorrhagic fever with renal syndrome (HFRS), sometimes fatal in humans. Considering the importance of detecting the hantavirus antigen, the construction of an immunosensor is essential. The structural and functional characteristics of camelid nanobodies (VHHs) encourage their application in the areas of nanobiotechnology, therapeutics, diagnostics, and basic research. Therefore, this study aimed to standardize stable bioconjugates using gold nanoparticles (AuNPs) and VHHs, in order to develop immunobiosensors for the diagnosis of hantavirus infection...
May 26, 2024: Molecular Diagnosis & Therapy
Yanan Wu, Lubanga Nasifu, Bangshun He
No abstract text is available yet for this article.
May 23, 2024: Molecular Diagnosis & Therapy
Qing-Hua Wang, Jing-Jing Yang, Wei Han, Hao-Nan Wang
No abstract text is available yet for this article.
May 23, 2024: Molecular Diagnosis & Therapy
Thimmaiah Bargavi Ram, Saravanan Krishnan, Jaison Jeevanandam, Michael K Danquah, Sabu Thomas
Cancer is a leading global cause of mortality, which underscores the imperative of early detection for improved patient outcomes. Biorecognition molecules, especially aptamers, have emerged as highly effective tools for early and accurate cancer cell identification. Aptamers, with superior versatility in synthesis and modification, offer enhanced binding specificity and stability compared with conventional antibodies. Hence, this article reviews diagnostic strategies employing aptamer-based biohybrid nano-biosensing technologies, focusing on their utility in detecting cancer biomarkers and abnormal cells...
May 22, 2024: Molecular Diagnosis & Therapy
Pei-Yun Ho, Yu-Chen Huang
BACKGROUND: Psoriasis is a chronic, inflammatory, T-cell-mediated disease with a multifactorial pathogenesis. MicroRNA (miRNA) alteration in psoriasis has been identified within the last few years. In particular, miR-146a levels were altered. However, previous studies have equivocal or even contradictory findings. OBJECTIVE: The current study aimed to perform a systematic review and meta-analysis to evaluate the miRNA expression profile in different tissues in patients with psoriasis...
May 22, 2024: Molecular Diagnosis & Therapy
Briana A Santo, Kerry E Poppenberg, Shiau-Sing Ciecierska, Jaims Lim, Ammad A Baig, Vinay Jaikumar, Kunal P Raygor, Tatsat R Patel, Munjal Shah, Elad I Levy, Adnan H Siddiqui, Vincent M Tutino
BACKGROUND: Transcriptomic profiling has emerged as a powerful tool for exploring the molecular landscape of ischemic stroke clots and providing insights into the pathophysiological mechanisms underlying stroke progression and recovery. In this study, we aimed to investigate the relationship between stroke clot transcriptomes and stroke thrombectomy outcome, as measured by early neurological improvement (ENI) 30 (i.e., a 30% reduction in NIHSS at 24 h post-thrombectomy). HYPOTHESIS: We hypothesized that there exist distinct clot gene expression patterns between good and poor neurological outcomes...
May 20, 2024: Molecular Diagnosis & Therapy
Monika Anna Rosochowicz, Katarzyna Kulcenty, Wiktoria Maria Suchorska
PURPOSE: HtrA1, HtrA2, HtrA3 and HtrA4 appear to be involved in the development of pathologies such as cancer. This systematic review reports the results of a literature search performed to compare the expression of HtrA family genes and proteins in cancer versus non-cancer tissues and cell lines, assess relationships between HtrA expression and cancer clinical features in cancer, and analyse the molecular mechanism, by which HtrA family affects cancer. METHODS: The literature search was conducted according to the PRISMA statement among four databases (PubMed, Web of Science, Embase and Scopus)...
May 8, 2024: Molecular Diagnosis & Therapy
Ryan Xin
Inflammatory bowel disease (IBD) is a complex disease that develops through a sequence of molecular events that are still poorly defined. This process is driven by a multitude of context-dependent genes that play different roles based on their environment. The complexity and multi-faceted nature of these genes make it difficult to study the genetic basis of IBD. The goal of this article is to review the key genes in the pathophysiology of IBD and highlight new technology that can be used in further research...
April 18, 2024: Molecular Diagnosis & Therapy
Tina Nie
Talicabtagene autoleucel (NexCAR19™) is a chimeric antigen receptor (CAR) T-cell therapy being developed by the Indian Institute of Technology, Bombay (IIT-B) and Immunoadoptive Cell Therapy (ImmunoACT) for the treatment of relapsed/refractory B-cell malignancies. Talicabtagene autoleucel contains autologous T cells from the patient, which have been modified to express a humanized anti-CD19 CAR that targets B cells. A single intravenous dose of talicabtagene autoleucel was associated with high response rates in pooled results from a phase I and phase II trial in patients with relapsed/refractory B-cell malignancies...
July 2024: Molecular Diagnosis & Therapy
Susan J Keam
Lifileucel (AMTAGVI™), a one-time autologous T cell therapy derived and expanded from tumour-infiltrating lymphocytes (TIL) from a patient's own tumour, is being developed by Iovance Biotherapeutics, Inc. for the treatment of cancer. Lifileucel was granted accelerated approval based on objective response rate (ORR) in February 2024 in the USA for use in adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor...
May 2024: Molecular Diagnosis & Therapy
Irene Santi, Heleen Vellekoop, Matthijs M Versteegh, Simone A Huygens, Winand N M Dinjens, Maureen Rutten-van Mölken
OBJECTIVES: We evaluated the prognostic value of the neurotrophic tyrosine receptor kinase (NTRK) gene fusions by comparing the survival of patients with NTRK+ tumours with patients without NTRK+ tumours. METHODS: We used genomic and clinical registry data from the Center for Personalized Cancer Treatment (CPCT-02) study containing a cohort of cancer patients who were treated in Dutch clinical practice between 2012 and 2020. We performed a propensity score matching analysis, where NTRK+ patients were matched to NTRK- patients in a 1:4 ratio...
April 14, 2024: Molecular Diagnosis & Therapy
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.